Regulatory Story
Go to market news section View chart   Print
RNS
Avingtrans PLC  -  AVG   

Interim Results

Released 07:00 28-Feb-2017

RNS Number : 9878X
Avingtrans PLC
28 February 2017
 

28 February 2017

Avingtrans plc

              

("Avingtrans" or the "Group")

 

Interim results for the six months ended 30 November 2016

 

Avingtrans plc, which designs, manufactures and supplies critical components, modules and associated services to the energy, medical and industrial sectors, today announces its preliminary results for the six months ended 30 November 2016. 

 

Financial Highlights

 

·     Revenue from continuing operations increased by 11% to £9.6 m (2016 H1: £8.6m)

·     Adjusted group EBITDA advanced to breakeven (loss 2016 H1: £0.7m)

·     Adjusted profit before tax improved to a loss of £0.2m (loss 2016 H1: £1.2m)

·     Adjusted diluted loss per share from continuing operations 0.4p (loss 2016 H1: 3.6p)

·     Cash outflow from operating activities £3.5m (2016 H1: £0.5m)

·     Net cash reduced to £27.8m (31 May 2016: Net cash £51.0m), following successful tender offer which returned £19.4m to shareholders

·     Interim dividend increased by 9%, to 1.2p per share (2016 H1: 1.1p)

 

Energy and Medical revenues up 11%, EBIT improved to breakeven in H1

·     Improving sales in continuing businesses - up 11% vs prior year

·     Divisional adjusted EBITDA of £0.5m, against prior year loss (loss 2016 H1: £0.2m)

·     Significant improvement in performance of Composite Products business

·     First Sellafield 3M3 (three-metre-cubed) prototype box delivered and fully approved

·     Chatteris facilities redevelopment for Sellafield is on time and on budget

·     Order book is strengthening: £9m / 10 year contract with Wuhan, China for NMR cryostats

·     China facility gearing-up for new contracts with Wuhan and Bruker

·     Post period end, acquisition of Scientific Magnetics Ltd, Abingdon, for £0.35m

 

Commenting on the results, Roger McDowell, Chairman, said:

"The successful tender offer was completed in early November 2016 and resulted in £19.4m being returned to shareholders. This was less cash than anticipated - a positive vote - leaving the group with cash balance of almost £28m, to enable future M&A and organic growth opportunities. M&A activity is now a principal focus of the management team, as we seek to build on past successes.

 

Operationally, progress with Sellafield and other new customers is on track and we were delighted to welcome the Sellafield team to the official opening of the new facility for 3M3 box manufacture at Chatteris, at the end of the first half. The Energy and Medical division performed in line with management expectations in the period and we look forward to the coming months, as we begin to capitalise on the recent contract wins with Sellafield, Rapiscan, Bruker and EDF."

 

"Our attractive structural growth markets and durable customer relationships mean that we remain optimistic about the future of Avingtrans."



 

Enquiries:

Avingtrans plc

Steve McQuillan, CEO

Stephen King, CFO 

 

0135 469 2391

N+1 Singer

Shaun Dobson

Lauren Kettle

 

020 7496 3000

Newgate
(Financial PR)
Adam Lloyd
Ed Treadwell

James Browne

020 7653 9850

 

About Avingtrans plc:

Avingtrans is engaged in the provision of highly engineered components, systems and services to the energy, medical, industrial and traffic management industries worldwide.    

 

Energy and Medical

 

Stainless Metalcraft Ltd - Chatteris, UK and Chengdu, China

Provider of safety-critical equipment for the energy, medical, science and research communities, worldwide, specialising in precision pressure and vacuum vessels and associated fabrications, sub-assemblies and systems.

 

Maloney Metalcraft Ltd - Aldridge, UK

Designs, manufactures and services oil and gas extraction and processing equipment, including process plant for dehydration, sweetening, drying and compression.

 

Crown International Ltd - Portishead, UK

Designs and manufactures market-leading pole and support systems for roadside signage and safety cameras, rail track signalling and gantries.

 

Composite Products Ltd - Buckingham, UK

Centre for composite technology, parts and assemblies, serving customers in industrial markets.

 

 

 

 



Chairman's Statement

 

Following a momentous prior year, in which we successfully disposed of our Aerospace division, we have now entered a rebuilding period, as previously communicated. We successfully completed the tender offer in the first half, returning £19.4m to shareholders. This was less cash than anticipated - a positive vote - leaving the group with a cash balance of almost £28m, to enable future M&A and organic growth opportunities.

 

Despite the current geopolitical uncertainties, we believe that the strength of our balance sheet puts us in a good position - we are not under any pressure to make acquisitions and it is a good time to have a healthy cash position. We are excited to note that, post period end, we acquired the business Scientific Magnetics Ltd, a manufacturer of superconducting magnet systems and cryogenics for MRI and other markets, for £0.35m. This small, but strategic acquisition, will act as the cornerstone of our vertical integration strategy in the medical market.

 

As is often the case, our Energy and Medical business is expected to be second half weighted, having won important projects in FY16, which we are in the process of ramping up - notably the on-going pre-production phase of Sellafield 3M3 Box operations at Metalcraft. So far, this is progressing positively, with Sellafield recently approving the first 3M3 prototype unit. Crown is also expected to enjoy a stronger second half, with new projects expected to convert to sales during this period.

 

As investors will be aware, the Sellafield project is the precursor to a significant expansion of long term business in the nuclear decommissioning sector. This first contract is for 1,100 waste storage containers over 10 years (worth £47m in revenue). We believe that Metalcraft remains well-placed to be a key partner for Sellafield in this programme over the next 30 years and to participate in further contracts in the sector, as and when these are tendered.

 

Thus, we consider that a long term partnership is developing with Sellafield, utilising Metalcraft's expertise in producing high integrity vessels and containers, on schedule and budget, as we have proven for many other markets. This is potentially transformational for the Energy business over the next few years. We are pleased with progress on other recently won contracts - especially with Rapiscan, which has improved the performance of Composite Products in Buckingham substantially.

 

New contract preparations are also proceeding to plan in China, concerning Bruker and Wuhan, for "NMR" (Nuclear Magnetic Resonance) vacuum vessel products.

 

During the period, we continued to invest in skills - especially apprentices - as part of our on-going journey towards world-class manufacturing capability. Our efforts have been recently rewarded at regional and national apprentice awards ceremonies and at the Nuclear Decommissioning Authority's (NDA) Supply Chain Awards, where we won the prestigious Minister's Award. Our Metalcraft business now ranks amongst the top 100 apprentice providers in the UK. I am particularly proud of our skills investment, as we continue to cultivate high quality engineering careers for young people.

 

In addition to the cash returned to shareholders in the period, the Board has declared an increased interim dividend, of 1.2 pence per share, once again underlining our commitment to consistently improve returns to our shareholders.

 

On behalf of our valued customers, our loyal investors and the Board, I would like to thank our employees for their continued dedication and hard work during the last few months, as we seek to transform Avingtrans once again and we all look forward towards the next exciting growth phase.

 

 

Roger McDowell

Chairman

27 February 2017

 

Strategic Review

Group Performance

Growth Strategy (PIE)

 

We are a precision engineering group, operating in differentiated, specialist niches in the supply chains of many of the world's best known engineering original equipment manufacturers. Our strategy is to build market-leading niche positions in our chosen sectors - currently Energy and Medical. Over the longer term, our acquisition strategy has enabled our businesses to develop the critical mass necessary to achieve market leadership.

Our core businesses have the capability to engineer products in Europe and produce those products partly, or wholly in Asia, allowing the Company and our customers to access low cost sourcing at minimum risk, as well as positioning us neatly in the development of the Chinese and Asian markets for our products. Metalcraft is well established in China, providing integrated supply chain options for our customers.

 

We have strengthened our capability to manage sophisticated outsourced manufacturing programmes for our customers, which has enabled us to build stronger and more durable long term relationships with the prospect of further sales growth. We remain focused on markets where we can sustain a competitive advantage and where the regulatory and technical requirements provide competitive barriers to entry.

The Group's clear objective is to continue the proven strategy of "buy and build" in regulated engineering niche markets, where we see consolidation opportunities, which can lead to significantly increased shareholder returns over the medium to long term. At the appropriate time we will seek to crystallise these gains with periodic sales of businesses at advantageous valuations and return the proceeds to shareholders. We call this strategy PIE - "Pinpoint-Invest-Exit". Previous deals - not least the recent disposal of Sigma - have clearly demonstrated the success of this approach, producing substantial increases in shareholder value. We have built strong brands and value from smaller constituent parts, we have demonstrated well-developed deal-making skills and we have also shown that we do not overpay for assets. The strategy to "buy and build" around smaller deals and consolidate relevant niches has significant potential to generate growth and shareholder value, as demonstrated with Sigma and JenaTec. Having built successful Avingtrans businesses in Germany, the USA and China, as well as the UK, M&A prospects will not be confined to the domestic market.

 

New Divisional Structure

In order to give greater structure and focus to the Group's growth strategy we will organise the operational management and financial reporting of the business around two core sectors: Energy and Medical. Both divisions have distinct markets and technological features making this organisational change a logical step:

Energy: where we are developing our position as a leading European supplier of energy industry process modules, vertically integrating this capability with the vessel manufacturing capability at Metalcraft and the recently acquired assets of Whiteley Read Engineering Ltd. This same vertical integration capability lends itself strongly to the nuclear decommissioning, life extension and "new nuclear" markets - in particular, nuclear waste storage containers - as well as a variety of other niches in the renewable energy sector.

Medical: Metalcraft's cryogenic vacuum vessel manufacturing pedigree, spanning over 40 years, makes us a supplier of choice to OEMs in markets where this capability is critical; notably in magnetic resonance imaging, nuclear magnetic resonance, proton therapy and related sectors. We enjoy a global market leading position in this particular supply niche. The recent acquisition of Scientific Magnetics Ltd adds considerable technology and engineering capability in MRI and NMR and underpins the potential to concentrate our medical businesses into a stand-alone division.

When the preliminary results for the year ending 31 May 2017 are published, management will also report on the operational and financial performance of the two divisions.

Operations

 

Energy and Medical Division (Metalcraft, Maloney Metalcraft, Composite Products, Crown)

 

The effects of the low oil price have now worked through at Maloney and we have most of our remaining resources focused elsewhere, following a residual phase of restructuring implemented in the period. We are now focused on the growth areas in the energy market, for example: energy storage; carbon capture; and nuclear power life extension and decommissioning.

As noted above, the initial modest fruits of recent contract wins began to mature in the period, with revenues increasing by 11% versus 2016 first half, a trend which we expect to continue in the second half. This resulted in a positive EBITDA for the division, in line with management expectations and representing a welcome improvement versus last year's first half loss, with notable improvement at Composite Products, Buckingham (retained after the Aerospace disposal).

 

Despite the recent oil price issues, the US Energy Information Administration forecasts a 48% increase in global energy consumption (between 2012 and 2040) mainly driven by population growth. This is positive for Metalcraft and Maloney, since we have interests in various parts of the energy cycle, from primary extraction, to generation, alternative energy storage and decommissioning. Decommissioning activities are steadily gathering pace, as this very long term issue is slowly grasped by the UK government and others around the world.

 

The demographics of a growing and ageing world population are encouraging for the medical imaging and diagnostics markets, so the business is well placed to benefit from external market drivers. There have been notable changes of ownership in some of the key players in the MRI sector recently, with Cannon acquiring Toshiba's Medical business unit post period end for $6bn and Siemens putting their Healthcare business up for sale. We continue to see new entrants penetrating the Chinese medical imaging market, which, in general, we view positively. These developments indicate that the sector will continue to spend money on developing new products and imaging techniques - eg the improved MRI diagnostic procedure for prostate cancer, as reported recently.

 

Summarising developments in the period, at the Energy and Medical businesses:

 

·     Metalcraft, Chatteris: business with Siemens and Cummins in the UK was again steady. The £47m, 10-year contract with Sellafield Ltd, to produce 3M3 boxes, for the storage of intermediate level nuclear waste, is progressing to plan. We have made excellent progress with facilities refurbishment and pre-production tests. The production set-up and prototyping phase will continue in the current financial year, with series production expected to commence in calendar 2018. Metalcraft is well-placed to be a key partner for Sellafield in this programme. The total number of 3M3 boxes required is now expected to be in excess of 70,000 over the entire programme life, worth an estimated £3bn, according to Sellafield's own estimates.

 

·    Metalcraft, Chengdu: results for the unit continued to improve year on year and we made good progress with the existing customers, as well as preparing for the new contracts with Bruker and Wuhan for "NMR" vessels.

 

·     Maloney Metalcraft, Aldridge: as noted elsewhere, the oil price effects continued to affect the business in the period, though this has now largely washed though, with a limited restructuring completed, to stabilise our position in the new $50 a barrel oil reality. The gas project contracts with Samsung and JGC Gulf International Co. Ltd progressed substantially in the period. Both have taken longer to complete than previously anticipated, due to customer originated programme changes. Work also commenced on the EDF contract. 

 

·    Crown, Portishead: Crown had a steady, if subdued first half. The "FET" carbon abatement trial in Wales concluded successfully and we are working to turn this application into a product of the future with FET. This technology promises to make small to medium diesel generators "clean", which is important in a future where the energy grid is more fragmented and localised. Other prospects with FET are also progressing, albeit slowly.

 

·    Composite Products, Buckingham: performance in the period improved markedly, versus H1 last year, as we began volume deliveries to Rapiscan. The second half performance will be similar and we anticipate further volume growth in the next financial year.

 

·    Whiteley Read Engineering Ltd, Rotherham: This small assets acquisition has already proven its worth, by successfully completing overspill activities from Maloney and Metalcraft, as well as widening our customer base in the Energy sector.

 

·    Scientific Magnetics Ltd, Abingdon: acquired in February 2017, this niche supplier of high power superconducting magnets and cryogenics brings considerable engineering capability, at a time when we expect to see new breakthrough technologies impacting the magnet designs of the future.

Financial Performance

Key Performance Indicators

 

The Group uses a number of financial key performance indicators to monitor the business, as set out below.

 

Revenue: continuing operations beginning to see impact of prior contract wins

Full year Group revenue of continuing operations was up by 11%, to £9.6m (2016 H1: £8.6m). Energy and Medical are beginning the ramp up of output for various recent contract wins, albeit modest improvement in H1.

 

The proportion of revenue derived from long term agreements (LTAs) of three years plus is increasing. We exited the previous financial year with almost £60m of LTAs signed and have since signed the Wuhan contact worth £9m and an extended contract with Siemens.

 

Profit: improving margins on rising volumes

Gross margins were 15.0% (2016 H1: 9.8%), improving as the margin mix of new contracts seeps in.

Adjusted EBITDA of continuing operations advanced significantly, to £0.5m (loss 2016 H1: £0.2m), as anticipated, due to increased turnover and improving product mix. The Composite Products performance improved considerably in H1, on rising demand.

 

Loss per Share: Improved for continuing operations.

Adjusted diluted loss per share for continuing operations improved to 0.4p, from a loss in 2016 H1 of 3.6p.

Funding and Liquidity: Balance sheet strong with Net Cash - tender offer returned £19.4m

The net cash outflow from operating activities was £3.5m (2016 H1: £0.5m), primarily due to Sigma disposal costs, as previously highlighted. Net Cash at the period end stood at £27.8m (31st May 2016: £51.0m) following the return of £19.4m (pre costs) of cash to shareholders via the tender offer. Having initially looked to return up to £28m, the Group's resultant cash position is therefore approximately £8m above prior expectations.

 

Dividend: steady progress continues

The Board again voted to underline our progressive dividend policy and we are pleased to be able to recommend an improved interim dividend of 1.2 pence per share (2016 H1: 1.1 pence per share). We intend to continue on this progressive path, subject to the outcome of our M&A activities. The dividend will be paid on 16 June 2017, to shareholders on the register at 26 May 2017.

People

 

Good governance dictates that the non-executive directors should be replaced periodically. As previously announced, Jeremy Hamer retired from the Avingtrans Board at the AGM in November. He is replaced as Audit Committee Chair by Les Thomas. The Board warmly thanks Jeremy for his very valuable contribution to Avingtrans over many years and we wish him the very best for the future.

Post period end, we have appointed a new General Manager for Metalcraft China. Significantly, he is a Chinese national, meaning that all Metalcraft employees there are Chinese, for the first time.

There were no other Board or top team management changes in the period, but we continued to develop and reinforce our management team in Energy and Medical. Skills availability remains challenging, but we do not expect to be unduly constrained by any shortages and we continue to invest in skills - e.g. through apprenticeships - notably at our training centre at Chatteris. Metalcraft's apprentice development has recently been recognised with regional and national awards.

 

Outlook

 

The Group is a niche engineering market leader in the Energy, Medical and Industrial sectors. Recent activity under our "Pinpoint-Invest-Exit" (PIE) strategy, such as the Sigma sale last year, demonstrates that we can produce excellent returns and deliver real proceeds back to shareholders. We will continue to be uncompromising about delivering value and we are not afraid to sell and return capital, as and when the timing is right.

Our investment in operational excellence continues to produce significant new business wins that support our results and provide good visibility of longer term earnings. We have an excellent customer base which we can build upon and differentiated product niches to exploit. We are very well placed to benefit from further market consolidation.

Our Energy and Medical businesses are clear leaders in their chosen markets, providing customers with consistent quality, as part of a world class supplier journey. Our Chinese presence is also providing a crucial additional competitive advantage.

 

With attractive structural growth markets and durable customer relationships, we remain optimistic about the future for Avingtrans. Future acquisition efforts will be conducted rigorously, with an underpinning ethos that any deal should be for the benefit of all stakeholders and should build sustainable long-term value. Investors are asked to endorse our strategy and join us in the next exciting phase of our development.

 

 

 

 

Roger McDowell                    Steve McQuillan                                 Stephen King

Chairman                                Chief Executive Officer                      Chief Financial Officer

27 February 2017                      27 February 2017                                  27 February 2017

 



Consolidated Income Statement (Unaudited)

for the six months ended 30 November 2016

 

6 months to

6 months to

Year to

 

30 Nov

2016

30 Nov

2015

31 May

2016

 

£'000

£'000

£'000





Revenue

9,593

8,606

21,177





Cost of sales

(8,155)

(7,763)

(18,028)


              

              

              

Gross profit

1,438

843

3,149

Distribution costs

(321)

(280)

(699)

Share based payment expense

(7)

(13)

(21)

Tender share buyback costs

(199)

-

-

Restructuring costs

(183)

(176)

(272)

Net proceeds on disposal of property

-

444

446

Other administrative expenses

(1,454)

(1,686)

(2,830)


              

              

              

Total administrative expenses

(1,843)

(1,431)

(2,677)


              

              

              

Operating loss

(726)

(868)

(277)





Finance income

159

1

554

Finance costs

(22)

(39)

(82)


              

              

              

(Loss)/profit before taxation

(589)

(906)

245

Taxation  (Note 3)

103

166

175


              

              

              

(Loss)/profit after taxation from continuing operations

(486)

(740)

420


             

             

             

Profit after taxation from discontinued operations

-

1,763

30,716


             

             

             

(Loss)/profit for the financial period

(486)

1,023

31,136


             

             

             

(Loss)/earnings per share:




From continuing operations




- Basic

(1.9)p

(2.7)p

1.5p

- Diluted

(1.9)p

(2.7)p

1.5p

From continuing and discontinued operations




- Basic

(1.9)p

3.7p

112.3p

- Diluted

(1.9)p

3.7p

111.4p


             

             

             





Consolidated statement of comprehensive income (Unaudited)

for the six months ended 30 November 2016


6 months to

6 months to

Year to


30 Nov

2016

30 Nov

2015

31 May

2016


£'000

£'000

£'000





(Loss)/profit for the period

(486)

1,023

31,136

Exchange differences on translation of foreign operations

11

(83)

(283)

Exchange differences recycled on disposal of subsidiary undertakings



477


              

              

              

Total comprehensive (loss)/ income for the period

(475)

940

31,330


             

             

             



Consolidated cash flow statement (Unaudited)

for the six months ended 30 November 2016

 


6 months to

6 months to

Year to


30 Nov

2016

30 Nov

2015

31 May

2016


£'000

£'000

£'000





Operating activities




Cash flows from operating activities

(3,466)

(645)

7,885

Finance costs paid

(22)

(68)

(146)

Income tax repaid

-

198

52


              

              

              

Net cash (outflow)/inflow from operating activities

(3,488)

(515)

7,791





Investing activities




Acquisition of subsidiary undertakings

-

-

(3,500)

Disposal of subsidiary undertakings

-

-

53,677

Finance income

159

1

554

Purchase of intangible assets

(146)

(323)

(766)

Purchase of property, plant and equipment

(82)

(348)

(1,062)

Proceeds from sale of intangible assets

-

-

9

Proceeds from sale of property, plant and equipment

-

1,283

1,319


              

              

              

Net cash (used)/generated by investing activities

(69)

613

50,231





Financing activities




Equity dividends paid

(305)

(277)

(830)

Repayments of bank loans

(244)

(790)

(4,156)

Repayments of obligations under finance leases

(149)

(380)

(1,176)

Proceeds from issue of ordinary shares

283

5

32

Purchase of shares - tender buyback

(19,383)

-

-

Borrowings raised

-

187

1,651


              

              

              

Net cash outflow from financing activities

(19,798)

(1,255)

(4,479)





Net (decrease)/increase in cash and cash equivalents

(23,355)

(1,157)

53,543

Cash and cash equivalents at beginning of period

52,923

(361)

(361)

Effect of foreign exchange rate changes

(265)

(46)

(259)


              

              

              

Cash and cash equivalents at end of period

(29,303)

(1,564)

52,923


               

               

               





 

 

Cashflows from operating activities (Unaudited)

for the six months ended 30 November 2016

 

6 months to

6 months to

Year to


30 Nov

2016

30 Nov

2015

31 May

2016


£'000

£'000

£'000





(Loss)/profit before income tax from continuing operations

(589)

(906)

245

Profit before income tax from discontinued operations

-

2,143

3,878





Adjustments for:




Depreciation of property, plant and equipment

246

664

1,520

Amortisation of intangible assets

86

582

983

Profit on disposal of property, plant and equipment

-

(498)

(489)

Finance income

(159)

(1)

(554)

Finance expense

22

68

146

Research and Development Expenditure Credit

-

(134)

(168)

Share based payment charge

7

22

36

Bargain purchase on acquisition

-

-

(172)





Changes in working capital




Increase in inventories

(539)

(1,926)

(2,327)

(Increase)/decrease in trade and other receivables

(33)

1,837

(556)

(Decrease)/increase in trade and other payables

(2,509)

(2,498)

5,339

Other non cash changes

2

2

4


              

              

              

Cash (outflow)/inflow from operating activities

(3,466)

(645)

7,885


               

               

               





 

 



 

Summarised consolidated balance sheet (Unaudited)

at 30 November 2016

 


30 Nov

30 Nov

31 May


2016

2015

2016


£'000

£'000

£'000





Non current assets




Goodwill

4,550

9,557

4,550

Other intangible assets

991

3,184

930

Property, plant and equipment

4,654

11,371

4,668

Deferred tax

6

64

6


                

                

                


10,201

24,176

10,154


                

                

                

Current assets




Inventories

3,622

12,655

3,046

Trade and other receivables: amounts falling due within one year

8,024

17,196

6,141

Trade and other receivables: amounts falling due within after year

1,450

-

1,450

Current tax asset

85

16

85

Cash and cash equivalents

34,674

5,115

56,503


                

                

                


47,855

34,982

67,225


                

                

                

Total assets

58,056

59,158

77,379


                

                

                





Current liabilities




Trade and other payables

(6,061)

(11,721)

(6,908)

Obligations under finance leases

(245)

(684)

(295)

Borrowings

(5,549)

(7,809)

(3,911)

Current tax liabilities

(129)

(510)

(129)


                

                

                

Total current liabilities

(11,984)

(20,724)

(11,243)


                

                

                





Non-current liabilities




Borrowings

(986)

(2,176)

(1,075)

Obligations under finance leases

(77)

(583)

(176)

Deferred tax

(128)

(800)

(132)


                

                

                

Total non-current liabilities

(1,191)

(3,559)

(1,383)


                

                

                

Total liabilities

(13,175)

(24,283)

(12,626)


                

                

                

Net assets

44,881

34,875

64,753


                

                

                

Equity




Share capital

916

1,386

1,387

Share premium account

11,173

10,877

10,903

Capital redemption reserve

814

814

814

Merger reserve

-

402

-

Translation reserve

3

(285)

(8)

Other reserves

180

180

180

Investment in own shares

(1,000)

(1,000)

(1,000)

Retained earnings

32,795

22,501

52,477


                

                

                

Total equity attributable to equity owners of the parent

44,881

34,875

64,753


                

                

                





 

Consolidated statement of changes in equity (Unaudited)

at 30 November 2016




Share

 capital

account

Share

 premium

account

Capital

 redemp-

tion

 reserve

Merger

 reserve

Trans-

lation

 reserve

Other

 Reserves

Investment

in own shares

Retained

 Earnings

  Total

£'000

£'000

£'000

£'000

£'000

£'000

£'000

£'000

£'000











At 1 June 2015

1,385

10,873

814

402

(202)

180

(1,000)

21,733

34,185

Shares issued

1

4

-

-

-

-

-

-

5

Dividend paid

-

-

-

-

-

-

-

(277)

(277)

Share-based payments

-

-

-

-

-

-

-

22

22

Transactions with owners

1

4

-

-

-

-

-

(255)

(250)

Profit for the period

-

-

-

-

-

-

-

1,023

1,023

Other comprehensive income









 

Exchange rate loss

-

-

-

-

(83)

-

-

-

(83)

Total comprehensive income for the year

 

-

 

-

 

-

 

-

 

(83)

 

-

 

-

 

1,023

 

940

At 30 Nov 2015

1,386

10,877

814

402

(285)

180

(1,000)

22,501

34,875











 

At 1 Dec 2015

 

1,386

 

10,877

 

814

 

402

 

(285)

 

180

 

(1,000)

 

22,501

 

34,875

Shares issued

1

26

-

-

-

-

-

-

27

Dividend paid

-

-

-

-

-

-

-

(553)

(553)

Transfer on disposal

-

-

-

(402)

-

-

-

402

-

Share-based payments

-

-

-

-

-

-

-

14

14

Transactions with owners

1

26

-

(402)

-

-

-

(137)

(512)

Profit for the period

-

-

-

-

-

-

-

30,113

30,113

Other comprehensive income










Exchange rate loss

-

-

-

-

(200)

-

-

-

(200)

Recycled on disposal

-

-

-

-

477

-

-

-

477

Total comprehensive income for the year

 

-

 

-

 

-

 

-

 

277

 

-

 

-

 

30,113

 

30,390

At 31 May 2016

1,387

10,903

814

-

(8)

180

(1,000)

52,477

64,753





















At 1 June 2016

1,387

10,903

814

-

(8)

180

(1,000)

52,477

64,753

Shares issued

13

270

-

-

-

-

-

-

283

Tender share buyback

(484)

-

-

-

-

-

-

(18,898)

(19,382)

Dividend paid

-

-

-

-

-

-

-

(305)

(305)

Share-based payments

-

-

-

-

-

-

-

7

7

Transactions with owners

(471)

270

-

-

-

-

-

(19,196)

(19,397)

Loss for the period

-

-

-

-

-

-

-

(486)

(486)

Other comprehensive income









 

Exchange rate gain

-

-

-

-

11

-

-

-

11

Total comprehensive income for the year

 

-

 

-

 

-

 

-

 

11

 

-

 

-

 

(486)

 

(475)

At 30 Nov 2016

916

11,173

814

-

3

180

(1,000)

32,795

44,881

 

 

 

Notes to the half year statement

30 November 2016

1.         Basis of preparation

The Group's interim results for the six month period ended 30 November 2016 are prepared in accordance with the Group's accounting policies which are based on the recognition and measurement principles of International Financial Reporting Standards ('IFRS') as adopted by the EU and effective, or expected to be adopted and effective, at 31 May 2017. As permitted, this interim report has been prepared in accordance with the AIM rules and not in accordance with IAS34 'Interim financial reporting'.

 

These interim results do not constitute full statutory accounts within the meaning of section 434 of the Companies Act 2006 and are unaudited. The unaudited interim financial statements were approved by the Board of Directors on 29 February 2017 and will shortly be available on the Group's website at http://www.avingtrans.plc.uk/pages/reports.html.

 

The consolidated financial statements are prepared under the historical cost convention as modified to include the revaluation of financial instruments. The accounting policies used in the interim financial statements are consistent with IFRS and those which will be adopted in the preparation of the Group's annual report and financial statements for the year ended 31 May 2017. The statutory accounts for the year ended 31 May 2016, which were prepared under IFRS, have been filed with the Registrar of Companies. These statutory accounts carried an unqualified Auditor's Report and did not contain a statement under either Section 498(2) or (3) of the Companies Act 2006.

2.         Segmental analysis

 

 



Energy and

Medical

Unallocated

Central

items

Total




£'000

£'000

£'000

6 months ended 30 Nov 2016

 






Revenue



9,593

-

9,593




                

              

              







Operating loss



(49)

(677)

(726)




                

              

              







Year  ended 31 May 2016

 






Revenue



21,177

-

21,177




                

              

              







Operating profit/(loss)



59

(286)

(227)




                

              

              







6 months ended 30 Nov 2015

 






Revenue



8,606

-

8,606




                

              

              







Operating (loss)



(428)

(440)

(868)




                

              

              








 

3.         Taxation

The taxation credit/(charge) is based upon the expected effective rate for the year ended 31 May 2017.

 

4.         (Loss)/earnings per share

Basic (loss)/earnings per share is based on the (loss)/earnings attributable to ordinary shareholders and the weighted average number of ordinary shares in issue during the year.

 

For diluted (loss)/earnings per share the weighted average number of ordinary shares is adjusted to assume conversion of all dilutive potential ordinary shares, being the CSOP and EMI share options.

 


6 months to

30 Nov 2016

No

6 months to

30 Nov 2015

No

Year to

31 May 2016

No

Weighted average number of shares - basic

25,576,758

27,712,449

27,725,452

Share Option adjustment

203,867

106,901

230,934


                

                

                

Weighted average number of shares - diluted

25,780,625

27,819,350

27,956,386


                

                

                






£'000

£'000

£'000

(Loss)/earnings from continuing operations

(486)

(740)

420

Share based payments

7

13

21

Restructuring costs

183

176

272

Tender share buyback costs

199

-

-

Net proceeds on disposal of property

-

(444)

(446)


        

        

        

Adjusted (loss)/earnings from continuing operations

(97)

(995)

267

From continuing operations:




Basic (loss)/earnings per share

(1.9)p

(2.7)p

1.5p

Adjusted basic (loss)/earnings per share

(0.4)p

(3.6)p

1.0p

Diluted (loss)/earnings per share

(1.9)p

(2.7)p

1.5p

Adjusted diluted (loss)/earnings per share

(0.4)p

(3.6)p

1.0p






        

        

        

Earnings from discontinued operations

-

1,763

30,716





Basic earnings per share

-

6.4p

110.8p

Diluted earnings per share

-

6.3p

109.9p


        

        

        

(Loss)/earnings attributable to shareholders

(97)

1,023

31,136





Basic (loss)/earnings per share

(1.9)p

3.7p

112.3p

Diluted (loss)/earnings per share

(1.9)p

3.7p

111.4p





 

The Directors believe that the above adjusted (loss)/earnings per share calculation from continuing operations is the most appropriate reflection of the Group performance.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR EAXAXASNXEFF
Close


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

 


Interim Results - RNS